https://www.selleckchem.com/products/rk-33.html
93, 95% CI 1.08-7.95; p = .035, OS HR = 9.07, 95% CI 1.17-70.26; p = .035) and MALT-IPI 1-2 (PFS HR = 2.67, 95% CI 1.12-6.31; p = .027, OS HR = 6.64, 95% CI 1.45-30.37; p = .015). CR following frontline therapy was associated with longer PFS (HR = 0.13, 95% CI 0.04-0.45; p = .001), but not OS. Using the Fine and Gray regression model with death without relapse/progression as a competing risk, RT and CR after frontline therapy were associated with lower risk of relapse (SHR = 0.34, 95% CI 0.12-0.96 p = .041 and SHR = 0.11, 95% CI 0.03-0.36
Me gusta
Comentario
Compartir
